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Neuroinflammation is associated with neurodegenerative disease.
PET radioligands targeting the 18-kDa translocator protein (TSPO)
have been used as in vivo markers of neuroinflammation, but there
is an urgent need for novel probes with improved signal-to-noise
ratio. Flutriciclamide (18F-GE180) is a recently developed third-
generation TSPO ligand. In this first study, we evaluated the opti-
mum scan duration and kinetic modeling strategies for 18F-GE180
PET in (older) healthy controls.Methods: Ten healthy controls, 6 TSPO
high-affinity binders, and 4 mixed-affinity binders were recruited. All
subjects underwent detailed neuropsychologic tests, MRI, and a
210-min 18F-GE180 dynamic PET/CT scan using metabolite-corrected
arterial plasma input function. We evaluated 5 different kinetic models:
irreversible and reversible 2-tissue-compartment models, a reversible
1-tissue model, and 2 models with an extra irreversible vascular com-
partment. The minimal scan duration was established using 210-min
scan data. The feasibility of generating parametric maps was also in-
vestigated using graphical analysis. Results: 18F-GE180 concentration
was higher in plasma than in whole blood during the entire scan du-
ration. The volume of distribution (VT) was 0.17 in high-affinity binders
and 0.12 in mixed-affinity binders using the kinetic model. The model
that best represented brain 18F-GE180 kinetics across regions was the
reversible 2-tissue-compartment model (2TCM4k), and 90min resulted
as the optimum scan length required to obtain stable estimates.
Logan graphical analysis with arterial input function gave a VT highly
consistent with VT in the kinetic model, which could be used for
voxelwise analysis. Conclusion: We report for the first time, to our
knowledge, the kinetic properties of the novel third-generation TSPO
PET ligand 18F-GE180 in humans: 2TCM4k is the optimal method
to quantify the brain uptake, 90 min is the optimal scan length, and
the Logan approach could be used to generate parametric maps.
Although these control subjects have shown relatively low VT, the
methodology presented here forms the basis for quantification for
future PET studies using 18F-GE180 in different pathologies.
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Microglia play a crucial role as the first line of defense when
neuronal damage occurs. Under normal conditions, microglial cells
are in a state of surveillance with elongated processes. During injury
or neurodegenerative processes, microglial cells become activated;
the activated state is mirrored by upregulation of translocator protein
(TSPO) (1,2). PET with TSPO-specific ligands provides an in vivo
technique to detect microglial activation (3).
11C-(R)-PK11195 PET has been used for more than 2 decades.
However, because of a low signal-to-background ratio and short
half-life (20 min), second-generation TSPO markers have been de-
veloped. These include 18F-FEPPA, 18F-FEDAA1106, 11C-vinpocetine,
11C-DAC, 11C-DAA1106, 11C-N1-methyl-2-phenylindol-3-ylglyoxylamide,
11C-CLINME, 11C-DPA-713, 18F-DPA-714, 18F-PBR06, and 11C-PBR28
(4). However, the results obtained by second-generation radioligands
in preclinical models have not been consistently reproduced in hu-
mans (5). Their quantification in humans suffers from 3 confounding
factors (6). The first factor is genetic: a single nucleotide polymor-
phism in the TSPO gene (rs6971) leads to an amino-acid substitution
(A147T) and reduced binding affinity. The second factor is the dis-
proportion between the high signal from the TSPO in the endothelial
cells of the blood–brain barrier (BBB) and venous sinuses and the
signal from the tissue, requiring appropriate kinetic correction (7).
The third factor is the difficulty in obtaining accurate estimates of
free plasma concentrations for proper quantification.
Flutriciclamide (18F-GE180) has been identified as a promising
TSPO tracer in preclinical models of stroke and lipopolysaccharide-
induced central nervous system inflammation (8,9). Here we report
the results of a study evaluating 18F-GE180 PET in healthy human
brains. We have investigated blood tracer concentrations, brain up-
take, quantification of binding via tracer kinetic modeling, optimal
scan length, and feasibility of generating parametric maps.
MATERIALS AND METHODS
Fifteen healthy controls (HCs) aged 50–85 y were recruited. Sub-
jects who were high-affinity binders (HABs 5 6) or mixed-affinity
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binders (MABs5 4) proceeded to MRI and PET scans, whereas low-
affinity binders (n 5 5) were excluded. Details of recruitment, de-
mography, and MRI acquisition are provided in the supplemental
materials (available at http://jnm.snmjournals.org).
GE180 PET
18F-GE180 was manufactured on the FASTlab (GE Healthcare)
(10). All subjects received 185 MBq of 18F-GE180 by bolus intrave-
nous injection (in 20 s) immediately before the PET scan. The scan
was acquired using a Biograph 6 PET/CT scanner (Siemens) (11). An
initial CT was acquired for patient position and for attenuation cor-
rection of PET images. The tracer was then injected, and dynamic
emission PET images were acquired over 210 min using predeter-
mined time frames: 6 · 15, 3 · 60, 5 · 120, 5 · 300, and 14 · 600 s.
Images were corrected for attenuation, random, and scattered emissions
based on the 3-dimensional ordinary Poisson ordered-subset expectation
maximization algorithm. Reconstruction of PET was performed using
filtered backprojection.
Blood Data
Arterial whole-blood activity was continuously monitored for
the first 15 min of the PET scan using the Allogg automated blood
sampling system with real-time online blood sampling. Ten discrete
arterial blood samples were taken at 5, 10, 15, 30, 60, 90, 120, 150,
180, and 210 min of the PET scan. The activity concentration was
measured in both whole blood and plasma by a well-counter and was
used to generate a plasma-to-blood ratio curve. The time course of
activity in the plasma can be estimated with a sigmoidal fitting using
the plasma-to-blood ratio model to the first 15 min of continuous
whole-blood data.
Metabolites of 18F-GE180 were measured by high-performance
liquid chromatography analysis (10) using discrete blood samples. A
2-exponential linear model was used to describe the parent fraction of
18F-GE180, which was applied to the plasma to generate the parent
plasma input function. SUV was applied to both total blood and parent
plasma with the formula:
SUV 5
18F-GE180  activity  concentration  ðkBq=mLÞ
18F-GE180  injected  dose  ðMBqÞ=body  weight  ðkgÞ
:
Finally, the time delay (the arrival of the 18F-GE180 bolus at the
peripheral sampling site) was determined using MICK.exe (quantitative
software for the PET analysis) and was performed using MATLAB 2014
(The MathWorks, USA) on a Windows platform.
Region-of-Interest (ROI) Analysis
Each subject underwent two 90-min PET scans with a 20-min break
in between; the realignment approach was necessary to realign the
second scan to the first scan. Head motions were corrected using the
frame-by-frame realignment tools in statistical parametric mapping.
On the basis of the visual resolution, the eighth frame (185–245 s) was
selected as the reference frame for each time frame realigning to. An
individualized object map in PET space was created with the following
procedure: MRI was coregistered to the PET add image (60–90 min), a
binary gray and white matter mask was created via segmentation, the
probabilistic ROI atlas (12) in MNI space was transformed into native
PET space, and a binary mask was applied to the ROI atlas to generate
individual ROIs. Regional time–activity curves were generated by sam-
pling the dynamic PET images with the individual ROIs for the following
merging regions: frontal, temporal, parietal, and occipital lobes and
whole brain. Additional sampling of the posterior cingulate, thalamus,
brain stem, whole medial temporal lobe, hippocampus, and cerebellum
was performed. The parahippocampus, anterior cingulate, and amygdala
were sampled as additional ROIs using Analyze 11.0 (AnalyzeDirect).
The SUV time–activity curve was generated for each 18F-GE180 dynamic
PET by dividing the ratio of 18F-GE180–injected dose over body weight.
Kinetic Modeling
Parent plasma input function and dynamic PET were used to
investigate the best kinetic model to compute 18F-GE180 total volume
of distribution (VT) from time–activity curves with MICK software
(Modeling-Input-function-Compartmental-Kinetics) and MATLAB.
We evaluated 5 different kinetic models (supplemental materials).
18F-GE180 tissue data were investigated with the reversible 1-tissue
2k (1TCM2k) model, the 2-tissue 4k (2TCM4k) model, and the irre-
versible 2-tissue 3k, for which k implies the rate constant for tracer
for different kinetic compartments. As tracer binds to BBB endothe-
lial cells, endothelia could significantly affect kinetic modeling
(7,13); therefore, we also considered 1 tissue with extra vascular
component (1TCM2k-1k) and 2-tissue with extra vascular compo-
nent (2TCM4k-1k). The additional component describes the trap-
ping of the tracer by the endothelial cells of blood vessels. The
Akaike information criterion (AIC) (14) is a statistical measure to
estimate the quality of fit of the predicted model against the actual
data using different statistical models. In simple terms, the AIC
values indicate the information lost when a candidate model is ap-
plied to estimate the real data, and the model with the smallest AIC
value should be selected as the preferred model, as it indicates the
best fit (15). To select the best model to quantify the tracer, AIC is
calculated using the following formula:
AIC 5 n · ln ðwrssÞ1 2m;
where m denotes number of parameters, n equals the sum of degrees
of freedom and number of parameters, and wrss denotes weighted
residual sum of squares (16). The AIC fraction was also calculated by
measuring the frequency of AIC preferences for each model across
all subjects (17). AIC was calculated for the following brain regions:
frontal, temporal, parietal, and occipital lobes; whole brain; posterior
cingulate; thalamus; striatum; brain stem; medial temporal lobe; hippo-
campus; and cerebellum. Coefficient of variation (CV) was measured to
assess dispersion and precision of parameters. We also evaluated the
separation in average binding between HAB and MAB classes.
Graphical Analysis
Graphical analysis was applied to investigate the feasibility of
generating parametric maps of 18F-GE180. We used the Logan plot to
generate pixel-wise parametric maps. Initially we calculated the opti-
mal threshold time by linear fit, the tissue-to-plasma ratio against the
time. 18F-GE180 parametric maps were generated with the parent
plasma input function and dynamic PET images using MICK para-
metric map software on MATLAB.
Optimization of Scan Length
The optimum scan duration was evaluated, measuring the percentage
change of k (rate constants) and VT, along with their CVat different time
durations, calculated at 60, 75, 90, 150, 180, and 210 min. k3 and k4
indicate the rate constant of 18F-GE180 in and out of the specific-bound
compartment, whereas the k3/k4 ratio represents the specific binding of
the tracer. Thus, the k3/k4 ratio was measured to investigate whether the
binding potential of 18F-GE180 was affected when the scanning time was
reduced.
Statistical Analysis
Statistical analysis of groupwise differences between different
kinetic models, different scan durations, and ROI VT in different ge-
netic groups was calculated in SPSS for Windows (version 22; SPSS).
A P value of less than 0.05 was regarded as a statistical difference.
The Pearson correlation was applied to measure the linear correlation
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between 2 groups of variables using SPSS. Repeated-measures
ANOVAwas applied to detect any overall differences between repeated
measurements.
RESULTS
Parent Plasma Input
Consistent with the preclinical work (8), the radiochromato-
gram revealed 3 identifiable radiolabeled metabolites and a parent
18F-GE180 in human plasma (Fig. 1A). The parent fraction of 18F-
GE180 gradually reduced from 90% to 60%. There was no group
difference between HABs and MABs in metabolic rates and
plasma-to-blood curve (Figs. 1B and 1C). The 18F-GE180 activity
concentration in plasma was 1.6-fold higher than in whole blood.
No difference in parent plasma input function between HABs and
MABs was found (Fig.1D).
Dynamic PET Image Time–Activity Curve
Because tracer concentrations are correlated with injected dose
and individual weight, we measured SUV time–activity curve values
at each time frame. The tracer activity concentration in the brain
peaked at 125 s, with SUV at 1.5, and then quickly washed out and
reached a plateau around 40 min. As a group, SUVs were significantly
higher in HABs than MABs in the temporal lobe (P 5 0.0001),
thalamus (P 5 0.0001), and striatum (P 5 0.0002) (Fig. 2). The
venous sinuses showed consistently highest tracer activity throughout
the scan, whereas gray matter showed around 30% higher activity
concentration than white matter.
Kinetic Modeling
Among 5 kinetic models, 2TCM4k showed the lowest AIC
values in frontal (259.6 6 5.4), temporal (246.4 6 4.5), parietal
(258.6 6 5.4), and occipital lobes (254.3 6 5.1) as a group (Fig.
3A). The 2TCM4k model also showed the highest AIC fraction
(Fig. 3B). Although the 2TCM3k irreversible model demonstrated
closer AIC values (,10% difference compared with the 2TCM4k
model), the Ki (net influx constant), demonstrating the overall net
rate of tracer uptake into tissue in the 2TCM3k model, showed
poor precision with a high CV (104% 6 85%) whereas VT in the
reversible 2TCM4k model had a CVof 21% 6 13%. On the basis
of the model curve fitting, 2TCM4k provided a good fit to 18F-GE180
activity, supported by smallest weighted residual sum square and
more random in residual’s sequence (similar number of residuals
above or below the model curve) using the Wald–Wolfowitz test.
In summary, the 2TCM4k is the preferred
method of analysis of 18F-GE180 PET. The
supplemental materials detail rate constants
(K1, k2, k3, and k4), blood volume, and VT,
applying the 2TCM4k model in HABs and
MABs, which showed good precision of pa-
rameter estimation.
VT
As a group, 10 HCs had low mean VT in
the whole brain but slightly higher in tem-
poral the lobe, occipital lobe, and thalamus
(Fig. 4). The thalamus, parahippocampus
(47%, P = 0.04), and cerebellum showed
significantly higher mean VT values in HABs
than in MABs (Table 1).
Scan Length
The 210-min data were excluded be-
cause variance was high toward the end of
the scan. Repeated ANOVA did not show
difference in the absolute VT when the scan
duration was reduced. In this study, the group
FIGURE 1. 18F-GE180 blood data. (A) HPLC analysis for 18F-GE180 at
15 min in HAB subject (solid line) and MAB subject (dashed line). (B)
18F-GE180 parent fraction in arterial plasma. (C) Plasma-to-blood ratio
in HABs (●) and MABs (▪). (D) SUV for parent plasma and whole blood
as group and parent plasma input function curve in either HAB or MAB
cohorts.
FIGURE 2. SUV corrected time–activity curves of 18F-GE180 in temporal and occipital lobes
(A and B), thalamus (C), and striatum (D) for HABs (○) and MABs (*).
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mean of k3/k4 ratio (HAB5 0.52 and MAB5 0.34) was calculated to
evaluate the results among different scan lengths, showing no differ-
ences with scan length reduction from 180 to 90 min. When the scan
length was further reduced to 75 min, the k3/k4 ratio remained the same
as with the 90-min data, but 4 individual subjects showed a 14%
reduction in k3/k4 ratio. Compared with 90-min scans, 60-min scans
showed a 51% reduction in k3/k4 ratio as a group. These data suggest
that for this cohort the optimal scan duration is 90 min.
Logan
Kinetic modeling suggested that 18F-GE180 has a reversible
feature, therefore we applied Logan graphical analysis (18) to
generate parametric maps. On the basis of linear fit of the whole
brain and the appropriate weight for different time points, dynamic
data from 20 to 90 min (8 data points) were selected to generate a
Logan straight line (slope5 0.1476 0.06 and intercept521,6236
387) for parametric maps (Fig. 5). The Logan VT values (supple-
mental materials) were correlated with 2TCM4k VT values, with a
strong correlation in 4 cortices and hippocampus in both HABs
(P , 0.0001) and MABs (P , 0.0001) (Fig. 6). The HABs showed
generally higher Logan VT values than MABs; however, there were
no statistically significant differences in this small sample.
DISCUSSION
To our knowledge, this is the first study evaluating different
approaches for PET modeling of the third-generation TSPO tracer
18F-GE180 in older healthy subjects, establishing the optimum
scanning time in this study population. There was consistently
higher 18F-GE180 activity in plasma than in whole blood, but
brain VT values generated from plasma input functions were
low (;0.16). Data were acquired for 210 min after injection of
18F-GE180, and 5 different kinetic models were evaluated in this
study. The 18F-GE180 VT remained unchanged when the scan
length was reduced to 90 min, but changes were observed when
the scan length was reduced to 75 and 60 min, suggesting that
90 min might be the minimal scan time for 18F-GE180 PET. The
2TCM4k model demonstrated the lowest AIC and CV among the
5 kinetic models, suggesting that the 2TCM4k model could be
the best model to estimate 18F-GE180 uptake. Compared with
the 2TCM4k model, Logan graphical analysis allows us to create
parametric maps and to estimate VT at the voxel level. Logan VT
was highly correlated with 2TCM4k VT in all cortices, indicating
that the Logan graphical analysis can be used to create unbiased
parametric VT maps for 18F-GE180.
Consistent with a preclinical study (8), high-performance liquid
chromatography revealed 3 separate 18F-GE180 plasma metabo-
lites, with a similar profile in HAB and MAB and no significant
differences between HABs and MABs in plasma-to-blood ratios.
The plasma-to-blood ratio for tracers crossing the BBB by passive
diffusion is close to unity at the beginning
of PET. 18F-GE180 showed a relatively
high plasma-to-blood ratio of 1.55, indicat-
ing higher concentration in plasma than red
blood cells. A persistently high plasma-to-
blood ratio throughout the scan reflects
poor membrane penetration of 18F-GE180
across red cell membranes. In vitro assays
of plasma protein binding of 18F-GE180 in
human samples showed a relatively high
percentage (97.4%) plasma protein bind-
ing, which was also seen with other TSPO
tracers.
Preclinical animal models showed that
18F-GE180 crosses the BBB readily. In
humans, 18F-GE180 demonstrated a relative-
ly low VT in the brain, possibly because of
low availability of the GE180 due to sig-
nificant plasma protein binding, low BBB
permeability, or clearance by efflux pumps.
FIGURE 3. Kinetic model selection. (A) AIC values for 5 models in
frontal, temporal, parietal, and occipital lobes and whole brain. (B)
Graph with AIC fraction, revealing frequency of AIC preferences for each
model across all subjects.
FIGURE 4. 18F-GE180 regional VT in 2TCM4k model. Regional VT with application of 2TCM4k
model in 11 ROI regions. Circle with black bar represents HABs, and square with white bar
represents MABs. M = medial; P = posterior.
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Despite the fact that species differences have been observed in
the BBB structure (19) and other novel brain PET tracers (20), the
significant difference observed between human and preclinical
models in 18F-GE180 could be primarily due to a significantly
higher binding to plasma pro-
tein in humans.
18F-GE180 preclinical
studies demonstrated that, in
rats, there is a clear regional
differentiation of high-TSPO-
expressing regions (olfac-
tory bulbs) compared with
low-TSPO-expressing re-
gions (striatum) (21). In this
study, 5 subjects (1 MAB and
4 HABs) revealed lowest
uptake in the striatum: 3
(MABs) showed lowest up-
take in the cerebellum and 2
(HABs) showed a more gen-
eralized distribution of TSPO
expression. This inconsistent
pattern suggests that a single
predefined reference region
for nonspecific binding may
not be appropriate for 18F-
GE180 in humans in this
age group.
Because TSPO expression
is low in the healthy brain,
the 18F-GE180 VT values were
relatively small in all ROI re-
gions (range, 0.15–0.20). A higher signal in the thalamus than other
regions was found, consistent with previous 11C-(R)-PK11195 studies
(22). However, VT values for 18F-GE180 suggest that tracer brain
uptake is relatively low compared with other TSPO PET radioligands,
though the impact of this radioligand as a microglial imaging marker
cannot be determined until we have results in specific disease condi-
tions. The significant inverse correlation between the 18F-GE180 in-
put function and the tracer uptake in the brain reflects the higher
uptake to plasma proteins in humans than animal models.
Interestingly, the significant inverse correlation between
18F-GE180 input function and VT in the brain for each binding
class separately, with a correlation coefficient greater than 0.9,
indicates that whole-brain VT can be almost entirely predicted
by plasma levels within each binding class. As we were unable
to estimate plasma free fractions reliably, the fluctuations in esti-
mated VT may be due to fluctuations in free plasma fractions
across subjects. Indeed, higher plasma protein binding would result
in higher plasma counts and lower VT. This observation replicates
similar observations in other TSPO tracers (13,23). Identification of
an optimal reference method would allow us to further refine the
analysis methods without the arterial input.
Most second-generation TSPO tracers, such as 11C-PBR28 and
11C-PBR111, demonstrated an association with the TSPO geno-
type, revealing a 30% higher uptake in the whole brain of HABs
than MABs. In this study, there was a 30%–40% higher uptake
in HABs, reaching significance in the thalamus, parahippocampus,
and cerebellum. Nevertheless, there was some overlap between
subjects; moreover, the study cohort was also small. Compared
with some second-generation TSPO tracers, 18F-GE180 may be
less sensitive to the TSPO binding affinity status and may behave
more like 11C-(R)-PK11195. One could argue, some of the vari-
ability seen in the MABs and HABs could be due to test–retest
TABLE 1
Regional VT for 18F-GE180 Applied 2TCM4k Model in All HCs, HABs, and MABs
18F-GE180
2TCM4K FL TL PL OL WB P-cing Thalamus
Brain
stem Striatum MTL Hippo CB
All subjects
Mean 0.15 0.16 0.15 0.17 0.15 0.16 0.20 0.19 0.15 0.17 0.17 0.15
SD 0.06 0.07 0.05 0.06 0.06 0.06 0.09 0.09 0.06 0.06 0.08 0.07
TSPO genetic
subgroup
HAB
Mean 0.17 0.18 0.17 0.20 0.17 0.18 0.24 0.21 0.17 0.19 0.20 0.18
SD 0.06 0.07 0.05 0.06 0.07 0.06 0.09 0.09 0.05 0.07 0.08 0.07
MAB
Mean 0.12 0.13 0.12 0.14 0.12 0.12 0.14 0.16 0.10 0.13 0.13 0.11
SD 0.05 0.05 0.05 0.05 0.05 0.05 0.06 0.09 0.05 0.05 0.06 0.05
HAB vs.
MAB
T test 0.11 0.09 0.12 0.06 0.11 0.07 0.04* 0.18 0.07 0.06 0.09 0.05*
Increase 39% 45% 36% 45% 40% 49% 73% 36% 64% 50% 51% 63%
*P , 0.05.
FL 5 frontal lobe; TL 5 temporal lobe; PL 5 parietal lobe; OL 5 occipital lobe; WB 5 whole brain; P-cing 5 posterior cingulate;
MTL 5 medial temporal lobe; Hippo 5 hippocampus; CB 5 cerebellum.
FIGURE 5. Individual 18F-GE180
Logan parametric maps in trans-
verse view are demonstrated with
corresponding MR image.
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variability, which we are evaluating. The high correlation be-
tween Logan VT and 2TCM4k VT suggests that Logan parametric
mapping could be used to generate pixelwise parametric VT maps.
Because Logan generally underestimates the VT (24), there
was no statistically significant difference between HAB and
MAB, potentially because of the small numbers in this pilot
study. Additionally, consistently with VT results, the Logan VT
parametric maps demonstrated heterogeneous distribution of
18F-GE180 uptake in the HCs. This heterogeneity was observed
in both HAB and MAB subgroups and was consistent with
2TCM4k model.
Although one of the limitations of this study is the small
sample size, this pilot study provides the first insight into the
performance of 18F-GE180 in the normal human brain and in-
formation about the parent plasma input function. Another lim-
itation is the exclusion of the low-affinity binders from the study,
and our laboratory is recruiting more participants to evaluate this
tracer further. The low expression of TSPO in the normal brain
could be another limitation of this study evaluating only HCs.
However, these scans were obtained with an arterial input func-
tion and an extensive scanning time of 210 min, providing signif-
icant information about the tracer kinetics and modeling of this
novel TSPO tracer for future use.
CONCLUSION
This pilot study provides preliminary brain uptake kinetics of
the novel TSPO tracer 18F-GE180 in HCs. We have demon-
strated for the first time, to our knowledge, that 18F-GE180
shows uptake into the brain of HCs and that the tracer VT could
be effectively modeled using 2TCM4k and Logan graphical
models to quantify the TSPO binding in the human brain.
The plasma-to-blood ratio and the rate of metabolism and input
functions were not different between HAB and MAB subjects.
We have also demonstrated that 90 min is the optimal scan
duration, providing enough information to generate the precise
and accurate estimates of VT. Semiquantitative SUV analysis
for tracer uptake demonstrated a good correlation with kinetic
modeling VT values. Logan graphical analysis with arterial in-
put function enables us to generate 18F-GE180 parametric maps
for voxelwise analyses.
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